{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:45:59Z","timestamp":1789681559624,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,4,24]],"date-time":"2013-04-24T00:00:00Z","timestamp":1366761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s10495-013-0854-2","type":"journal-article","created":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T23:21:21Z","timestamp":1367364081000},"page":"1060-1070","source":"Crossref","is-referenced-by-count":43,"title":["Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-\u03baB inhibition and Bcr\/Abl protein deletion"],"prefix":"10.1007","volume":"18","author":[{"given":"Wei","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,24]]},"reference":[{"key":"854_CR1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.leu.2402879","volume":"17","author":"CA Schiffer","year":"2003","unstructured":"Schiffer CA, Hehlmann R, Larson R (2003) Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia 17:691\u2013699","journal-title":"Leukemia"},{"key":"854_CR2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7:441\u2013453","journal-title":"Nat Rev Cancer"},{"key":"854_CR3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/sj.onc.1203467","volume":"19","author":"J Voss","year":"2000","unstructured":"Voss J, Posern G, Hannemann JR et al (2000) The leukaemic oncoproteins Bcr\u2013Abl and Tel\u2013Abl (ETV6\/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene 19:1684\u20131690","journal-title":"Oncogene"},{"key":"854_CR4","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/sj.onc.1203484","volume":"19","author":"NN Danial","year":"2000","unstructured":"Danial NN, Rothman P (2000) JAK-STAT signaling activated by Abl oncogenes. Oncogene 19:2523\u20132531","journal-title":"Oncogene"},{"key":"854_CR5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0301-472X(03)00069-9","volume":"31","author":"D Kirchner","year":"2003","unstructured":"Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G (2003) Mechanisms of Bcr\u2013Abl-mediated NF-kappaB\/Rel activation. Exp Hematol 31:504\u2013511","journal-title":"Exp Hematol"},{"key":"854_CR6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V86.3.1148.1148","volume":"86","author":"A Bedi","year":"1995","unstructured":"Bedi A, Barber JP, Bedi GC et al (1995) BCR\u2013ABL-mediated inhibition of apoptosis with delay of G2\/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86:1148\u20131158","journal-title":"Blood"},{"key":"854_CR7","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1128\/MCB.15.10.5531","volume":"15","author":"D Cortez","year":"1995","unstructured":"Cortez D, Kadlec L, Pendergast AM (1995) Structural and signaling requirements for BCR\u2013ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15:5531\u20135541","journal-title":"Mol Cell Biol"},{"key":"854_CR8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/sj.cdd.4400400","volume":"5","author":"S Dan","year":"1998","unstructured":"Dan S, Naito M, Tsuruo T (1998) Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR\u2013ABL tyrosine kinase, CGP 57148. Cell Death Differ 5:710\u2013715","journal-title":"Cell Death Differ"},{"key":"854_CR9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells. Nat Med 2:561\u2013566","journal-title":"Nat Med"},{"key":"854_CR10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"854_CR11","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg E, Griffin JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines. Blood 95:3498\u20133505","journal-title":"Blood"},{"key":"854_CR12","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","volume":"95","author":"P Coutre le","year":"2000","unstructured":"le Coutre P, Tassi E, Varella-Garcia M et al (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95:1758\u20131766","journal-title":"Blood"},{"key":"854_CR13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1054\/drup.2000.0176","volume":"4","author":"GW Krystal","year":"2001","unstructured":"Krystal GW (2001) Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist Updat 4:16\u201321","journal-title":"Drug Resist Updat"},{"key":"854_CR14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"854_CR15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399\u2013401","journal-title":"Science"},{"key":"854_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr\u2013Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"854_CR17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.11248","volume":"92","author":"S Soverini","year":"2007","unstructured":"Soverini S, Iacobucci I, Baccarani M, Martinelli G (2007) Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 92:437\u2013439","journal-title":"Haematologica"},{"key":"854_CR18","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","volume":"14","author":"A Quintas-Cardama","year":"2008","unstructured":"Quintas-Cardama A, Cortes J (2008) Therapeutic options against BCR\u2013ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 14:4392\u20134399","journal-title":"Clin Cancer Res"},{"key":"854_CR19","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"854_CR20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S et al (2010) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28:398\u2013404","journal-title":"J Clin Oncol"},{"key":"854_CR21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27:107\u2013112","journal-title":"Leukemia"},{"key":"854_CR22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/pca.900","volume":"17","author":"A Stojakowska","year":"2006","unstructured":"Stojakowska A, Michalska K, Malarz J (2006) Simultaneous quantification of eudesmanolides and thymol derivatives from tissues of Inula helenium and I. royleana by reversed-phase high-performance liquid chromatography. Phytochem Anal PCA 17:157\u2013161","journal-title":"Phytochem Anal PCA"},{"key":"854_CR23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1055\/s-2001-16478","volume":"67","author":"VM Dirsch","year":"2001","unstructured":"Dirsch VM, Stuppner H, Vollmar AM (2001) Cytotoxic sesquiterpene lactones mediate their death-inducing effect in leukemia T cells by triggering apoptosis. Planta Med 67:557\u2013559","journal-title":"Planta Med"},{"key":"854_CR24","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1248\/bpb.25.1370","volume":"25","author":"T Konishi","year":"2002","unstructured":"Konishi T, Shimada Y, Nagao T, Okabe H, Konoshima T (2002) Antiproliferative sesquiterpene lactones from the roots of Inula helenium. Biol Pharm Bull 25:1370\u20131372","journal-title":"Biol Pharm Bull"},{"key":"854_CR25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0960-894X(00)00686-7","volume":"11","author":"NJ Lawrence","year":"2001","unstructured":"Lawrence NJ, McGown AT, Nduka J, Hadfield JA, Pritchard RG (2001) Cytotoxic Michael-type amine adducts of alpha-methylene lactones alantolactone and isoalantolactone. Bioorg Med Chem Lett 11:429\u2013431","journal-title":"Bioorg Med Chem Lett"},{"key":"854_CR26","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.tiv.2010.06.007","volume":"24","author":"HC Pal","year":"2010","unstructured":"Pal HC, Sehar I, Bhushan S, Gupta BD, Saxena AK (2010) Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa. Toxicol In Vitro 24:1599\u20131609","journal-title":"Toxicol In Vitro"},{"key":"854_CR27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1087057111398486","volume":"16","author":"Y Shi","year":"2011","unstructured":"Shi Y, Bao YL, Wu Y et al (2011) Alantolactone inhibits cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway. J Biomol Screen 16:525\u2013535","journal-title":"J Biomol Screen"},{"key":"854_CR28","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1073\/pnas.1019625108","volume":"108","author":"YY Wang","year":"2011","unstructured":"Wang YY, Zhao LJ, Wu CF et al (2011) C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 108:2450\u20132455","journal-title":"Proc Natl Acad Sci USA"},{"key":"854_CR29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.intimp.2010.02.003","volume":"10","author":"M Funakoshi-Tago","year":"2010","unstructured":"Funakoshi-Tago M, Nakamura K, Tsuruya R et al (2010) The fixed structure of Licochalcone A by alpha, beta-unsaturated ketone is necessary for anti-inflammatory activity through the inhibition of NF-kappaB activation. Int Immunopharmacol 10:562\u2013571","journal-title":"Int Immunopharmacol"},{"key":"854_CR30","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","volume":"12","author":"JY Reuther","year":"1998","unstructured":"Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr (1998) A requirement for NF-kappaB activation in Bcr\u2013Abl-mediated transformation. Genes Dev 12:968\u2013981","journal-title":"Genes Dev"},{"key":"854_CR31","doi-asserted-by":"crossref","first-page":"34910","DOI":"10.1074\/jbc.M304189200","volume":"278","author":"JL Hanson","year":"2003","unstructured":"Hanson JL, Anest V, Reuther-Madrid J, Baldwin AS (2003) Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways. J Biol Chem 278:34910\u201334917","journal-title":"J Biol Chem"},{"key":"854_CR32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1097-2765(03)00223-5","volume":"12","author":"S Rocha","year":"2003","unstructured":"Rocha S, Campbell KJ, Perkins ND (2003) p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell 12:15\u201325","journal-title":"Mol Cell"},{"key":"854_CR33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1476-4598-9-112","volume":"9","author":"Z Lu","year":"2010","unstructured":"Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J (2010) Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr\u2013Abl. Mol Cancer 9:112","journal-title":"Mol Cancer"},{"key":"854_CR34","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2004-10-4135","volume":"105","author":"ML Guzman","year":"2005","unstructured":"Guzman ML, Rossi RM, Karnischky L et al (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105:4163\u20134169","journal-title":"Blood"},{"key":"854_CR35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2009.10.013","volume":"291","author":"B Xu","year":"2010","unstructured":"Xu B, Guo X, Mathew S et al (2010) Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Lett 291:200\u2013208","journal-title":"Cancer Lett"},{"key":"854_CR36","doi-asserted-by":"crossref","first-page":"21683","DOI":"10.1073\/pnas.1016311108","volume":"107","author":"JH Mao","year":"2010","unstructured":"Mao JH, Sun XY, Liu JX et al (2010) As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR\u2013ABL in chronic myelogenous leukemia. Proc Natl Acad Sci USA 107:21683\u201321688","journal-title":"Proc Natl Acad Sci USA"},{"key":"854_CR37","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cbt.4.4.1702","volume":"4","author":"ZN Demidenko","year":"2005","unstructured":"Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA, Blagosklonny MV (2005) Kinase-addiction and bi-phasic sensitivity-resistance of Bcr\u2013Abl- and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther 4:484\u2013490","journal-title":"Cancer Biol Ther"},{"key":"854_CR38","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2006-02-005579","volume":"109","author":"GA Bartholomeusz","year":"2007","unstructured":"Bartholomeusz GA, Talpaz M, Kapuria V et al (2007) Activation of a novel Bcr\/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109:3470\u20133478","journal-title":"Blood"},{"key":"854_CR39","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1349-7006.2006.00269.x","volume":"97","author":"N Orsolic","year":"2006","unstructured":"Orsolic N, Golemovic M, Quintas-Cardama A et al (2006) Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci 97:952\u2013960","journal-title":"Cancer Sci"},{"key":"854_CR40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.cdd.4400868","volume":"8","author":"RH Decker","year":"2001","unstructured":"Decker RH, Dai Y, Grant S (2001) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ 8:715\u2013724","journal-title":"Cell Death Differ"},{"key":"854_CR41","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"EA Nelson","year":"2011","unstructured":"Nelson EA, Walker SR, Weisberg E et al (2011) The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117:3421\u20133429","journal-title":"Blood"},{"key":"854_CR42","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2009-03-211466","volume":"116","author":"R Tanaka","year":"2010","unstructured":"Tanaka R, Squires MS, Kimura S et al (2010) Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR\u2013ABL-positive leukemic cells. Blood 116:2089\u20132095","journal-title":"Blood"},{"key":"854_CR43","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM, Boschelli F et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr\u2013Abl+ neoplastic cells. Cancer Res 66:11314\u201311322","journal-title":"Cancer Res"},{"key":"854_CR44","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/sj.leu.2404735","volume":"21","author":"H Yan","year":"2007","unstructured":"Yan H, Wang YC, Li D et al (2007) Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. Leukemia 21:1488\u20131495","journal-title":"Leukemia"},{"key":"854_CR45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.seminhematol.2010.06.006","volume":"47","author":"BZ Carter","year":"2010","unstructured":"Carter BZ, Mak DH, Cortes J, Andreeff M (2010) The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol 47:362\u2013370","journal-title":"Semin Hematol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-013-0854-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-013-0854-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-013-0854-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T03:27:13Z","timestamp":1595734033000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-013-0854-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,24]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1007\/s10495-013-0854-2","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,24]]}}}